Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Materno-fetal hyperoxygenation for fetal left heart underdevelopment
2024-512679-11-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxygen in Cardiovascular Malformation (CVM) and hypoplastic left heart syndrome (HLHS) (2 arms), sponsored by Universitätsklinikum Erlangen. Planned start Mar 2024; status: authorised.
02
Drugs
oxygen
03
Conditions
Cardiovascular Malformation (CVM)hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on 2024-512679-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512679-11-00.